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The pyruvate kinase isozymes MI and M2 are structurally and immunologically closely related. To obtain an antibody 
which discriminates between these two forms, a synthetic tetradecapeptide with a sequence specific for pyruvate kinase 
type M2 from rats was constructed. Antisera from rabbits, immunized with this peptide, reacted specifically with the 
M2-type holoenzyme of both rat and human origin, and did not cross-react with the Ml-type isozyme. This was estab- 
lished by immunoblot analysis, both under dissociating and non-dissociating conditions. 
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1. INTRODUCTION 
Pyruvate kinase (ATP : pyruvate 2-O-phospho- 
transferase, EC 2.7.1.40) catalyzes one of the last 
steps in glycolysis, the conversion of phosphoenof- 
pyruvate to pyruvate. Four isozymes have been 
described in mammalian tissues, named the Ml, 
M2 (or K), L, and R type [1,2]. 
Pyruvate kinase (PK) is a tetramer, and when 
two or more subunit types are synthesized 
simultaneously within the same cell, hybrid iso- 
zymes are formed [3]. These hybrids, of which the 
subunit composition is designated by subscripts 
e.g. (M2)3M1, can easily be separated electro- 
phoretically. 
The Ml and M2 isozymes are structurally and 
immunologically closely related [4] and it has been 
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shown that these two forms are produced by two 
different mRNAs, transcribed from the same gene 
[5,6]. Recently, Noguchi et al. [7,8] determined the 
complete nucleotide sequences for both Ml- and 
M2-type PK from rat by sequencing the cDNAs. 
The derived amino acid sequences turned out to be 
identical except for one region of 45 residues. Even 
within this region the Ml and M2 sequences show a 
high degree of homology and therefore it is not sur- 
prising that conventional antibodies raised against 
the M2 type cross-react with the Ml type, and vice 
versa. 
In order to obtain antibodies specific for the M2 
isozyme, we constructed a synthetic tetradecapep- 
tide. The sequence of this peptide was chosen from 
the M2-type specific region of rat PK, as elucidated 
by Noguchi et al. [8]. Immunization of rabbits with 
this peptide, coupled to keyhole limpet hemo- 
cyanin as a carrier protein, resulted in antibodies 
not only reacting with the peptide, but also with the 
M2-type isozyme and not cross-reacting with the 
M 1 isozyme. 
2. MATERIALS AND METHODS 
Substrates, nucleotides and auxiliary enzymes for the deter- 
mination of pyruvate kinase activity and fructose 1,6-bisphos- 
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phate were obtained from Boehringer (Mannheim, FRG). Di- 
thiothreitol and keyhole limpet hemocyanin (KLH) were from 
Sigma (St. Louis, MO). SDS, acrylamide, bisacrylamide and 
EDAC were from Bio-Rad (Richmond, CA). All other 
chemicals used were of the highest purity available. 
2.1. Production of antipeptide antibodies 
A tetradecapeptide was synthesized by standard solid-phase 
methods. The sequence of this peptide is shown in fig. 1. 
The crude preparation was loaded on a Sep-Pak Cl8 cartridge 
(Waters Associates, Milford, MA) in 0.1% trifluoroacetic acid; 
the peptide was eluted with 0.1% trifluoroacetic acid in 50% 
acetonitrile and lyophilized. 
The synthesized peptide was coupled to KLH as a carrier pro- 
tein, using I-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCI 
as the coupling reagent. KLH (5.4 mg in 0.54 ml HzO) and pep- 
tide (5 mg in 0.5 ml HzO) were mixed and EDAC (11 mg in 
0.1 ml phosphate buffered saline) was added. Coupling was 
allowed to proceed for 2 h at room temperature under rotation. 
Consecutively, the mixture was extensively dialyzed against 
saline to remove excess of EDAC. Antisera against the peptide 
were prepared by priming two New Zealand white rabbits via in- 
tramuscular injections with 1 mg of the peptide-carrier con- 
jugate in 1 ml saline, emulsified with 1 ml complete Freund’s 
adjuvant (Gibco, Grand Island, NY). After three weeks, the 
rabbits were boosted with 1 mg of the immunogen emulsified in 
Freund’s incomplete adjuvant and boosted again at 1 month in- 
tervals. 
The titer against the peptide was measured by ELISA, using 
peptide or peptide conjugated to bovine serum albumin as the 
antigen [9,10]. 
Twelve weeks after the first immunization the sera of both 
rabbits reacted specifically with the peptide. The serum titers 
could not be increased by a further booster and therefore both 
rabbits were bled at week thirteen and the sera were collected. 
2.2. Preparation of tissue and cell extracts 
Differentiated and anaplastic medullary thyroid carcinomas 
from rats (DMTC and AMTC, respectively) were maintained as 
described elsewhere [ 111. The human glioma cell line HS 683 and 
the rat glioblastoma cell line C-6 (American Type Culture Col- 
lection, Rockville, MD) were cultured as described in [12]. 
Tumorous and normal tissues were homogenized in 3 vols of ice- 
cold extraction buffer containing 50 mM Tris-HCl (ph 7.5), 
0.1 M KCl, 0.5 M sucrose, 10 mM MgCIz, 0.5 mM dithio- 
threitol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 
1 mM diisopropylfluorophosphate and 1 mM fructose 1,6-bis- 
phosphate. Cell pellets (2 x 10’ cells) were homogenized by 
sonication in 0.3 ml of the same buffer. The homogenates were 
centrifuged (20 min. 40000 x g) and the supernatants (soluble 
fraction) and pellets (particulate fraction) were stored at 
- 80°C. 
2.3. Purification of pyruvate kinase isozymes 
PK type M2 was purified from AMTC by chromatography on 
a Blue-Sepharose CL-6B column (Pharmacia, Uppsala, 
Sweden) [13]. PK type R was partially purified from the hemo- 
lysate of human erythrocytes by a fractionated ammonium 
sulfate precipitation [ 141. 
PK activity was measured as described by Biicher and 
Pfleiderer [ 151. 
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2.4. Electrophoresis and immunoblotting 
SDS-electrophoresis was carried out in 11% polyacrylamide 
gels according to Laemmli [16]. Gels were either stained with 
Coomassie brilliant blue or used for immunoblotting. 
Separated proteins were electrophoretically transferred (2 h, 
60 V, 4°C) to nitrocellulose (Schleicher and Schiill, Kassel, 
FRG) in 25 mM Tris/l92 mM glycine (pH 8.3) and 20% 
methanol (v/v) using a Bio-Rad Trans-Blot apparatus. After 
blocking the remaining binding sites with 10 mM Tris-HCI 
(pH 7.4), 0.9% NaCI, 1% gelatin and 0.05% Tween-20, the 
blots were incubated (2 h, 20°C) with the antipeptide antiserum, 
diluted 1 : 2000 in the same buffer. The sheets were then treated 
with peroxidase conjugated goat anti-rabbit IgG (Nordic, Til- 
burg, The Netherlands) (1 h, 2O”C), washed and the peroxidase 
visualized by chloronaphthol staining. 
Separation of PK isozymes by electrophoresis on cellulose 
acetate strips and subsequent staining was performed as de- 
scribed previously [ll]. For immunoblot analysis the separated 
proteins were transferred to nitrocellulose by vacuum blotting in 
a slabdrier (Pharmacia, Uppsala, Sweden) for 2 h at room 
temperature. The blot was then treated as described above, ex- 
cept that staining was performed with 3,3’-diaminobenzidine. 
3. RESULTS 
The antiserum, raised against the synthetic pep- 
tide with a sequence specific for the M2 subunit of 
PK from rat tissues, also reacted with the complete, 
denatured M2 subunit. This was established by 
subjecting purified PK isozymes as well as tissue or 
cell extracts from human and rat origin to SDS- 
PAGE, followed by transfer of the separated pro- 
teins to nitrocellulose and immunoblotting (fig.2). 
Purified M2-type PK from AMTC of rat was clear- 
ly recognized by the antiserum (lane 3). In the solu- 
ble fraction of the rat glioblastoma cell line C-6 
(containing predominantly (M2)4 and a minor 
amount of (M2)3Ml isozymes, see below) only one 
protein band with a molecular mass of about 
60 kDa was detected by the antipeptide antibodies 
(fig.2, lane 2), and no protein band at all in the par- 
ticulate fraction (lane 1). Rat skeletal muscle, 
which contains the (Ml)4 isozyme, did not show 
any reaction in the immunoblot (lane 4). So, the 
antibody appeared to be very specific for PK as 
shown by SDS-PAGE of whole tissue homo- 
genates. Furthermore, the antiserum could 
specifically recognize the M2 subunit of PK from 
rats and did not cross-react with the Ml subunit. 
Identical results were obtained when using PK 
from human tissues. The antiserum only reacted 
with the M2 subunit of PK (from glioma cell line), 
but not with the Ml (from skeletal muscle) nor with 
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M24ype 388 Ile-Tyr-His-Leu-Gln-Leu-Phe-Glu-Glu-Leu-Ar~-Ar~-Leu-Ala-Pro- 
Ml-type 388 Val-Phe-His-Arg-Leu-Leu-Phe-Glu-Glu-Leu-Ala-Arg-Ala-Ser-Ser- 
Ile-Thr-Ser-As~-Pro-Thr-Glu-Ala-Ala-Ala-Val-Gly-Ala-Val-Glu- 
Gln-Ser-Thr-Asp-Pro-Leu-Glu-Ala-Met-Ala-Met-Gly-Ser-Val-Glu- 
Ala-Ser-Phe-Lys-Cys-Cys-Ser-Gly-Ala-Ile-Ile-Val-Leu-Thr-Lys 
Ala-Ser-Tyr-Lys-Cys-Leu-Ala-Ala-Ala-Leu-Ile-Val-Leu-Thr-Glu 
Fig. 1. Ammo acid sequences specific to the M 1- and MZ-type PK. according to Noguchi et al. [8]. The sequence of the constructed syn- 
thetic peptide is underlined. 
the R subunit (partially purified from erythrocytes) 
(not shown). 
Electrophoresis of PK on cellulose acetate was 
performed under non-dissociating conditions in 
order to separate the tetrameric isozymes. DMTC 
of rat contained both the (Ml)4 and the (M2)4 
homotetramer as well as the intermediate hybrids 
(fig.3, lane l), as can be visualized by staining for 
enzyme activity. As mentioned before, rat skeletal 
PK 
1 2 3 4 5 12345 
muscle contained the (Ml)4 isozyme (lane 2) and 
the C-6 cell line the (M2)4 enzyme and some of the 
(M2)jMl hybrid (lane 3). The corresponding im- 
munoblot shows that the (M2)4 isozyme from 
DMTC and C-6 was recognized by the antipeptide 
antiserum, but not the (Ml)4 enzyme from muscle 
and DMTC (fig.3). The (M2)xMl hybrid also gave 
a weak, but visible reaction with the antiserum. 
Interestingly, the antiserum revealed a certain 
B 
Fig.2. The particulate (lane 1) and the soluble fraction (lane 2) of an extract of C-6 glioblastoma cell line, purified PK type M2 from 
AMTC (lane 3) and a cytosolic extract of rat skeletal muscle (lane 4), prepared as described in section 2, were resolved by SDS-gel elec- 
trophoresis in 11% polyacrylamide. The proteins were either stained with Coomassie blue (A) or transferred to nitrocellulose for reac- 
tion with the antipeptide antiserum (B). Samples in lanes 2 and 4 contained equal amounts of PK activity (0.1 U); the sample in lane 
3 contained 0.2 U PK activity. Prestained chicken PK was used as standard (lane 5). 
393 
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Fig.3. Cytosolic extracts of DMTC (lane l), rat skeletal muscle (lane 2) and C-6 glioblastoma cell line (lane 3). prepared as described 
in section 2, were subjected to electrophoresis on cellulose acetate, and the separated isozymes were either visualized by staining for en- 
zyme activity (A) or subjected to Western blotting and subsequent incubated with the antipeptide antiserum (B). Samples contained 
10 mU PK activity for activity staining and 30 mU PK activity for blotting. Ml and M2 subunits are designated as M and K, respective- 
ly, according to the nomenclature used by Ibsen [Z]. 
amount of (M2)4 in the muscle extract, which was 
not seen after enzyme activity staining (fig.3, lane 
2). This can be explained by the presence of fibro- 
blasts and blood vessels in skeletal muscle tissue, 
which are known to contain the (M2)4 enzyme. 
This observation demonstrates the specificity and 
sensitivity of the antipeptide antiserum for the 
M2-type enzyme. Again, the same results were ob- 
tained on human tissues. 
4. DISCUSSION 
Conventional prepared antibodies raised against 
M2-type PK cross-react with the Ml type, and vice 
versa, due to the high homology between the Ml 
and the M2 isozyme. The elucidation of the com- 
plete nucleotide sequences of both Ml- and 
M2-type PK from rat by Noguchi and co-workers 
[S] prompted us to find a new approach for obtain- 
ing specific antibodies against M2-type pyruvate 
kinase. The primary structures of the Ml and M2 
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type were identical except for one region of 45 
amino acids [8]. From this region a sequence of 14 
residues was chosen, in which the differences be- 
tween the two isozymes were most frequent, and a 
corresponding synthetic tetradecapeptide with a 
M2-specific sequence was constructed (see fig. 1). 
Antibodies obtained after immunization not 
only reacted with the peptide, but also with the 
M2-type holoenzyme from rat as well as human 
origin, both in native tetrameric form and when 
dissociated in subunits. The antiserum proved to be 
very specific, as no reaction was found against the 
Ml, L, or R subunit of PK, nor against any other 
protein. This was demonstrated by immunoblot- 
ting experiments after SDS-PAGE and cellulose 
acetate electrophoresis. These results confirm the 
M2-type specificity of the synthesized peptide. 
It has been suggested by Noguchi et al. [8] that 
the subunit specific sequence of 45 amino acids of 
the M2-type PK might be important for mediating 
the allosteric properties of this isozyme. Therefore, 
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it might be possible that the antipeptide antiserum, 
directed against a part of this sequence, had an ef- 
fect on some kinetic features of the M2 enzyme. 
However, no alterations in the kinetic behavior of 
the (M2)4 enzyme could be observed in the presence 
of the antiserum (not shown). 
The applicability of the antibody in immuno- 
histochemistry is now being studied. The antibody 
may be helpful in understanding the isozymic shift 
from Ml- towards M2-type PK in various tumors 
[12,17-191, for instance in human gliomas, in 
which a strong correlation exists between isozyme 
composition, degree of histological differentiation 
and postoperative survival [19]. In these studies, 
the isozyme composition is determined in homo- 
genates of whole tissue specimens, using either 
electrophoretical methods or the property of the 
M2 enzyme to be inhibited by ATP [20] or L- 
alanine [ 191. The M2-specific antipeptide an- 
tiserum may enable us to determine the expression 
of PK isozymes in individual cells during develop- 
ment and carcinogenesis. 
In this report we used a synthetic peptide for the 
production of specific antibodies. Compared with 
the production of monoclonal antibodies, this 
method has the advantage that specific regions of 
interest can be chosen from the protein concerned 
beforehand, while the resulting antibodies will in 
fact have a ‘monoclonal’ character. 
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